Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TRXB, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| TRB-061 | Moderate-to-severe Atopic Dermatitis | Phase 1 · NCT06934252 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TRXB holds $90.9M in cash and short-term investments and burns about $11.6M/quarter from operations, an estimated runway of 23.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Based on our current operating plan, we believe these resources, together with the net proceeds from our IPO, will be sufficient to fund our operations and capital expenditure requirements into the second half of 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TRXB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| LILLY & Co ELI 10% owner |
Insider | 5,480,872 | 19.04% | 2026-10-13 |
| SVLSF VI, LLC 10% owner |
Insider | 3,011,818 | 10.46% | 2026-10-08 |
| PFIZER INC. (13-5315170) | 5%+ holder (13G) | 1,965,066 | 6.83% | 2026-10-08 |
| SV Biotech Crossover Opportunities Fund | 5%+ holder (13D) | 1,920,667 | 6.67% | 2026-10-08 |
| Johnson & Johnson Innovation - JJDC, Inc | 5%+ holder (13G) | 1,475,302 | 5.12% | 2026-10-13 |
| Alexandria Venture Investments, LLC 10% owner |
Insider | 1,346,501 | 4.68% | 2026-10-13 |
| Carol Giltner Gallagher Director · +17,500 options |
Insider | 251,471 | 0.87% | 2026-10-08 |
| Laura Berner Chief Operating Officer |
Insider | 168,574 | 0.59% | 2026-10-08 |
| Joel S Marcus Director · +17,500 options |
Insider | 41,871 | 0.15% | 2026-10-13 |
| Peter Hirth Director · +17,500 options |
Insider | 38,202 | 0.13% | 2026-10-08 |
| Ali Zarrin Chief Scientific Officer |
Insider | 18,111 | 0.06% | 2026-10-08 |
Share count 28,788,654 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TRXB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →